Skip to main content
Premium Trial:

Request an Annual Quote

InDevR Wins $3M SBIR Award

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics company InDevR will use a $3 million grant from the National Institute of Allergy and Infectious Diseases to develop microarray tools based on technology it licensed from the University of Colorado, Boulder, the firm said today.

The three-year Phase II Small Business Innovation Research Grant will fund development of the FluChip integrated molecular diagnostic platform that the firm first plans to use to develop an influenza screening test.

The grant, titled "Simultaneous Screening for A/H3N2, A/H1N1, A/H5N1 and B Influenza Viruses," follows a two-year $600,000 Phase I award that InDevr used to refine a low-density microarray assay for detecting influenza virus.

This round of funding will go to combine the FluChip microarray with the ampliPHOX detection method, also developed using CU-licensed technology, into a cartridge-based diagnostic platform.

CU Associate VP of Technology Transfer David Allen said in a statement that combining the two technologies "represents a promising and innovative approach" for diagnosing influenza.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.